Exagen Inc Cash Flow Conversion Efficiency
Exagen Inc cash flow conversion efficiency. Based on the latest financial reports, Exagen Inc (XGN) has a cash flow conversion efficiency ratio of 0.326x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.99 Million) by net assets ($12.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Exagen Inc (2012–2025)
Cash flow conversion efficiency of Exagen Inc from 2012 to 2025. This chart illustrates how Exagen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View XGN stock price and chart for real-time trading data and today's change.
Exagen Inc Cash Flow Conversion Ratio Explained
Exagen Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Exagen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Exagen Inc ranked by their cash flow conversion efficiency. Also see Exagen Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Brainchip Holdings Ltd
AU:BRN
|
-0.273x |
|
Compania Espanola de Viviendas en Alquiler SA
MC:CEV
|
0.006x |
|
GP-Act III Acquisition Corp. Class A Ordinary Share
NASDAQ:GPAT
|
-0.002x |
|
Crown Reserve Acquisition Corp. I Class A Ordinary Shares
NASDAQ:CRAC
|
0.000x |
|
Aekyung Industrial Co Ltd
KO:018250
|
-0.005x |
|
LIFELINE SPAC I OYJ A EO1
F:0CD
|
N/A |
|
Sekerbank TAS
IS:SKBNK
|
0.497x |
|
Vieworks Co. Ltd
KQ:100120
|
0.043x |
Annual Cash Flow Conversion Efficiency for Exagen Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Exagen Inc from 2012 to 2025. Review XGN cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $17.45 Million | $-13.62 Million | -0.781x | +43.90% |
| 2024-12-31 | $9.54 Million | $-13.28 Million | -1.392x | -118.42% |
| 2023-12-31 | $22.69 Million | $-14.46 Million | -0.637x | +15.82% |
| 2022-12-31 | $42.46 Million | $-32.14 Million | -0.757x | -217.23% |
| 2021-12-31 | $84.94 Million | $-20.27 Million | -0.239x | +29.11% |
| 2020-12-31 | $41.84 Million | $-14.08 Million | -0.337x | -92.94% |
| 2019-12-31 | $55.66 Million | $-9.71 Million | -0.174x | -112.63% |
| 2018-12-31 | $-6.73 Million | $-9.30 Million | 1.381x | -41.59% |
| 2017-12-31 | $-4.64 Million | $-10.97 Million | 2.365x | +340.77% |
| 2015-12-31 | $-22.18 Million | $-11.90 Million | 0.537x | -30.00% |
| 2014-12-31 | $-14.06 Million | $-10.77 Million | 0.766x | +105.04% |
| 2013-12-31 | $451.00K | $-6.87 Million | -15.222x | -881.67% |
| 2012-12-31 | $4.82 Million | $-7.48 Million | -1.551x | -- |
About Exagen Inc
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead test… Read more